See more : Tait Marketing & Distribution Co., Ltd. (5902.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of ICON Public Limited Company (ICLR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ICON Public Limited Company, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- China ZhengTong Auto Services Holdings Limited (CZASF) Income Statement Analysis – Financial Results
- Electronic Sensor Technology, Inc. (ESNR) Income Statement Analysis – Financial Results
- Caprolactam Chemicals Limited (CAPRO.BO) Income Statement Analysis – Financial Results
- Tantia Constructions Limited (TANTIACONS.NS) Income Statement Analysis – Financial Results
- WAM Microcap Limited (WMI.AX) Income Statement Analysis – Financial Results
ICON Public Limited Company (ICLR)
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.12B | 7.74B | 5.48B | 2.80B | 2.81B | 2.60B | 1.76B | 1.67B | 1.57B | 1.50B | 1.34B | 1.12B | 945.73M | 900.04M | 887.61M | 865.25M | 630.72M | 455.60M | 0.00 | 296.92M | 225.73M | 156.56M | 116.16M | 80.77M | 55.80M | 42.10M |
| Cost of Revenue | 5.72B | 5.53B | 3.97B | 1.99B | 1.97B | 1.83B | 1.03B | 961.33M | 908.98M | 903.17M | 845.41M | 718.13M | 611.92M | 541.39M | 507.78M | 489.24M | 354.48M | 256.26M | 0.00 | 162.56M | 122.37M | 83.37M | 63.80M | 42.04M | 29.30M | 0.00 |
| Gross Profit | 2.40B | 2.21B | 1.51B | 808.03M | 831.70M | 769.49M | 726.96M | 705.15M | 666.00M | 600.15M | 490.65M | 396.87M | 333.81M | 358.66M | 379.83M | 376.01M | 276.24M | 199.33M | 0.00 | 134.36M | 103.35M | 73.18M | 52.36M | 38.72M | 26.50M | 42.10M |
| Gross Profit Ratio | 29.56% | 28.60% | 27.52% | 28.89% | 29.64% | 29.64% | 41.34% | 42.31% | 42.29% | 39.92% | 36.72% | 35.59% | 35.30% | 39.85% | 42.79% | 43.46% | 43.80% | 43.75% | 0.00% | 45.25% | 45.79% | 46.75% | 45.08% | 47.94% | 47.49% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 319.28M | 317.00M | 318.56M | 322.27M | 332.90M | 308.74M | 277.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.52M | 6.74M | 7.17M | 4.51M | 3.56M | 5.20M | 3.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 776.36M | 778.75M | 585.33M | 341.69M | 336.75M | 325.79M | 323.74M | 325.73M | 326.79M | 336.46M | 313.93M | 280.78M | 255.86M | 232.69M | 230.91M | 248.78M | 187.99M | 136.57M | 0.00 | 88.81M | 71.12M | 48.95M | 36.31M | 27.35M | 18.00M | 0.00 |
| Other Expenses | 667.72M | 569.51M | 314.99M | 74.38M | 61.55M | 65.92M | 61.30M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 41.47M | 27.73M | 19.01M | 14.95M | 0.00 | 11.17M | 7.31M | 6.02M | 4.98M | 3.23M | 2.00M | 0.00 |
| Operating Expenses | 1.44B | 1.35B | 900.32M | 416.07M | 398.30M | 392.37M | 395.02M | 385.30M | 384.46M | 389.00M | 360.45M | 327.30M | 294.55M | 266.56M | 272.38M | 276.51M | 207.00M | 151.52M | 0.00 | 99.98M | 78.42M | 54.97M | 41.29M | 30.58M | 20.00M | 0.00 |
| Cost & Expenses | 7.16B | 6.88B | 4.87B | 2.41B | 2.37B | 2.22B | 1.43B | 1.35B | 1.29B | 1.29B | 1.21B | 1.05B | 906.47M | 807.95M | 780.16M | 765.74M | 561.48M | 407.78M | 0.00 | 262.54M | 200.80M | 138.34M | 105.09M | 72.62M | 49.30M | 0.00 |
| Interest Income | 5.01M | 2.35M | 574.00K | 2.72M | 6.86M | 4.76M | 2.35M | 1.48M | 1.31M | 1.15M | 986.00K | 1.15M | 1.19M | 1.76M | 752.00K | 2.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 336.70M | 229.73M | 182.42M | 15.07M | 6.42M | 13.61M | 12.99M | 13.01M | 3.99M | 785.00K | 1.29M | 1.97M | 1.64M | 1.13M | 3.53M | 4.11M | 0.00 | 0.00 | 0.00 | 281.00K | 0.00 | 0.00 | 0.00 | 575.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 585.95M | 614.73M | 360.33M | 94.61M | 91.92M | 65.92M | 61.25M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 32.66M | 27.73M | 18.89M | 14.84M | 0.00 | 10.60M | 7.27M | 5.97M | 4.96M | 3.23M | 2.00M | 0.00 |
| EBITDA | 1.52B | 1.41B | 739.43M | 488.83M | 532.19M | 451.76M | 401.94M | 379.43M | 339.21M | 263.69M | 168.67M | 111.09M | 69.32M | 127.73M | 140.86M | 130.11M | 88.25M | 62.77M | 0.00 | 31.94M | 45.55M | 32.23M | 24.23M | 16.05M | 8.50M | 42.10M |
| EBITDA Ratio | 18.74% | 18.57% | 16.85% | 17.48% | 17.64% | 17.22% | 19.33% | 23.26% | 21.54% | 18.13% | 13.90% | 10.18% | 9.28% | 14.00% | 15.87% | 15.04% | 13.99% | 13.78% | 0.00% | 15.34% | 14.28% | 15.48% | 13.82% | 16.09% | 15.23% | 100.00% |
| Operating Income | 956.15M | 795.24M | 608.47M | 391.97M | 433.41M | 377.12M | 331.95M | 311.69M | 281.54M | 202.35M | 121.17M | 69.57M | 29.44M | 92.10M | 107.45M | 99.50M | 69.24M | 47.82M | 0.00 | 34.38M | 24.93M | 18.21M | 11.08M | 8.15M | 6.50M | 42.10M |
| Operating Income Ratio | 11.78% | 10.27% | 11.10% | 14.01% | 15.45% | 14.53% | 18.88% | 18.70% | 17.88% | 13.46% | 9.07% | 6.24% | 3.11% | 10.23% | 12.11% | 11.50% | 10.98% | 10.50% | 0.00% | 11.58% | 11.04% | 11.63% | 9.53% | 10.09% | 11.65% | 100.00% |
| Total Other Income/Expenses | -331.69M | -227.39M | -181.85M | -10.30M | -6.42M | -8.74M | -10.28M | -11.52M | -2.69M | 366.00K | -302.00K | -796.00K | -448.00K | 629.00K | -2.78M | -1.22M | 2.74M | 3.64M | 0.00 | 979.00K | -9.10M | -5.60M | -4.62M | 2.52M | 2.60M | -32.49M |
| Income Before Tax | 624.47M | 567.85M | 196.68M | 382.18M | 426.99M | 368.38M | 327.67M | 300.17M | 278.85M | 202.72M | 120.87M | 68.70M | 29.00M | 92.72M | 104.67M | 98.28M | 71.98M | 51.46M | 0.00 | 34.67M | 25.28M | 19.33M | 13.60M | 9.19M | 9.10M | 0.00 |
| Income Before Tax Ratio | 7.69% | 7.34% | 3.59% | 13.66% | 15.22% | 14.19% | 18.63% | 18.01% | 17.71% | 13.48% | 9.05% | 6.16% | 3.07% | 10.30% | 11.79% | 11.36% | 11.41% | 11.29% | 0.00% | 11.68% | 11.20% | 12.35% | 11.70% | 11.38% | 16.31% | 0.00% |
| Income Tax Expense | 11.75M | 59.41M | 41.33M | 50.75M | 51.13M | 45.56M | 54.72M | 37.99M | 39.31M | 30.25M | 18.05M | 10.36M | 6.12M | 5.65M | 10.38M | 19.97M | 15.83M | 12.92M | 0.00 | 8.93M | 7.00M | 5.13M | 2.62M | 3.12M | 1.60M | 38.20M |
| Net Income | 612.34M | 505.30M | 153.19M | 327.81M | 373.99M | 322.82M | 272.94M | 262.18M | 239.54M | 172.47M | 102.81M | 58.35M | 22.88M | 87.07M | 94.30M | 78.12M | 55.96M | 38.30M | 0.00 | 25.74M | 18.28M | 14.20M | 10.98M | 6.07M | 7.50M | 3.90M |
| Net Income Ratio | 7.54% | 6.53% | 2.79% | 11.72% | 13.33% | 12.44% | 15.52% | 15.73% | 15.21% | 11.47% | 7.70% | 5.23% | 2.42% | 9.67% | 10.62% | 9.03% | 8.87% | 8.41% | 0.00% | 8.67% | 8.10% | 9.07% | 9.45% | 7.51% | 13.44% | 9.26% |
| EPS | 7.46 | 6.20 | 2.28 | 6.29 | 6.94 | 5.96 | 5.04 | 4.75 | 4.08 | 2.80 | 1.69 | 0.97 | 0.38 | 1.46 | 1.61 | 1.34 | 1.95 | 1.35 | 0.00 | 1.94 | 1.55 | 1.22 | 0.97 | 0.55 | 0.69 | 0.28 |
| EPS Diluted | 7.40 | 6.13 | 2.25 | 6.24 | 6.88 | 5.90 | 4.98 | 4.65 | 3.97 | 2.73 | 1.65 | 0.96 | 0.37 | 1.44 | 1.57 | 1.30 | 1.88 | 1.33 | 0.00 | 1.88 | 1.50 | 1.16 | 0.92 | 0.51 | 0.63 | 0.25 |
| Weighted Avg Shares Out | 82.10M | 81.53M | 67.11M | 52.86M | 53.86M | 54.12M | 54.13M | 55.25M | 58.75M | 61.50M | 60.91M | 59.97M | 60.38M | 59.72M | 58.64M | 58.25M | 28.71M | 28.31M | 13.86M | 13.27M | 11.81M | 11.66M | 11.29M | 11.05M | 10.91M | 13.93M |
| Weighted Avg Shares Out (Dil) | 82.72M | 82.47M | 68.07M | 53.28M | 54.33M | 54.74M | 54.87M | 56.41M | 60.29M | 63.13M | 62.25M | 60.68M | 61.07M | 60.64M | 59.90M | 60.22M | 29.75M | 28.86M | 13.86M | 13.70M | 12.18M | 12.24M | 11.94M | 11.82M | 11.92M | 15.92M |
ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference.
ICON: Starting Valuations And Business Returns Are 2 Major Hurdles
The market's response after ICON's Q3 numbers indicates it is forecasting a period of better business for the company in 2024. ICLR's projected earnings growth out to 2025 is 9-14% on sales growth of 5-7%. Despite a strong company, current...
3 Reasons Growth Investors Will Love Icon PLC (ICLR)
Icon PLC (ICLR) could produce exceptional returns because of its solid growth attributes.
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
Nvidia is leading the artificial intelligence revolution, and that's not likely to change. The world will always need new drugs, and Icon can help bring them to market.
ICLR or DOCS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Doximity (DOCS). But which of these two stocks offers value investors a better bang for their buck right now?
ICON plc to Present at Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at Upcoming Investor Conferences.
4 Stocks to Invest in for Remarkable Earnings Acceleration
Invest in stocks such as Confluent (CFLT), Pinterest (PINS), ICON (ICLR) and ImmunoGen (IMGN) for solid earnings acceleration.
Here is Why Growth Investors Should Buy Icon PLC (ICLR) Now
Icon PLC (ICLR) possesses solid growth attributes, which could help it handily outperform the market.
ICON Public Limited Company (ICLR) Q3 2023 Earnings Call Transcript
ICON Public Limited Company (NASDAQ:ICLR ) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET Company Participants Kate Haven - VP, IR Steven Cutler - CEO & Director Brendan Brennan - CFO Conference Call Participants Eric Coldwell -...
Icon PLC (ICLR) Beats Q3 Earnings and Revenue Estimates
Icon PLC (ICLR) came out with quarterly earnings of $3.30 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports